OVARIAN CANCER and US: palliative

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label palliative. Show all posts
Showing posts with label palliative. Show all posts

Wednesday, January 04, 2012

Anticancer therapies in specialized palliative care—a multicenter survey (HOPE project)



In conclusion, this study shows that the use of ACT refers to a distinguishable subgroup of palliative care patients in distinct institutions and is therefore more than a mere expansion of the therapeutic (pharmacologic) spectrum in palliative care. The continuing debate about integrating ACT into palliative care concepts and about early integration of palliative care into oncology has now gained new arguments.

Thursday, July 28, 2011

abstract: Quantity, Design, and Scope of the Palliative Oncology Literature



"...Comparing 2004 with 2009, we found an increase in the proportion of original studies among all palliative oncology publications but no significant difference in study design or research topic. We identified significant deficiencies in the quantity, design, and scope of the palliative oncology literature...."

Sunday, July 11, 2010

Cochrane Collaboration review: Palliative surgery versus medical management for bowel obstruction in ovarian cancer - Review



CONCLUSIONS:

We found only low quality evidence comparing palliative surgery and medical management for bowel obstruction in ovarian cancer. Therefore we are unable to reach definite conclusions about the relative benefits and harms of the two forms of treatment, or to identify sub-groups of women who are likely to benefit from one treatment or the other. However, there is weak evidence in support of surgical management to prolong survival.

Tuesday, June 15, 2010

Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions



CONCLUSIONS: While retrospective reviews evaluating hospice are challenging, our data suggest no detrimental impact on survival for hospice patients (vs non hospice). Continued evaluation for patients at the end-of-life is necessary in order to optimize resource utilization.

Friday, January 29, 2010

Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites? -- The Oncologist



"Despite the very strong preclinical evidence for an obligatory role of VEGF in the formation of malignant ascites and for a possible therapeutic efficacy of anti-VEGF therapies in the setting of malignant effusions, there are currently no reports from clinical studies addressing this point in cancer patients..........To date, only very few patients with malignant ascites have received i.p. bevacizumab and, therefore, this route of administration as well as this particular patient population need to be examined stringently regarding the safety of the treatment. However, we believe that i.p. application might be the route of choice in this particular setting."